Heart failure is a major health issue, with no current treatments effectively preventing or reversing the harmful cardiac fibrosis that leads to declining heart function. Chronic inflammation is a key factor in this fibrosis, but there are no strategies to balance harmful and healing immune responses locally without affecting the entire immune system. Dendritic cells (DCs) play a crucial role in managing immune responses, offering a potential therapeutic approach for heart diseases. Researchers have developed engineered dendritic cells (iCDCs) that target fibrosis and suppress immune responses, protecting against harmful cardiac changes. In mouse models of heart injury and stress, iCDCs reduced inflammation, improved heart blood flow, and maintained heart function. These cells work by directly suppressing harmful cell activation and promoting beneficial immune cells. In primate models, iCDCs also improved heart health without causing widespread immune suppression. This research suggests that targeting immune responses in specific heart areas could be a promising treatment for heart failure.
QUESTION: How might the development of targeted immune therapies like iCDCs change the future of heart disease treatment?
Engineered immunosuppressive dendritic cells protect against cardiac remodelling
